Sunday, 15 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleCrunchbase News

Exclusive: Fintech Offers Startups Alternative To Venture Debt With A New Model To Finance Customer Acquisition Costs

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: Exclusive: Fintech Offers Startups Alternative To Venture Debt With A New Model To Finance Customer Acquisition Costs Date: 2026-09-17 14:00 Source: https://news.crunchbase.com/venture/fintech-alternative-funding-customer-acquisition-skalar/ <p>Technology companies routinely spend he…
Opening lines of the source · Crunchbase News · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Venture capital only serves the top 1% of tech businesses; more than half of the remaining 99% could potentially be underwritten by Skalar's product, which currently lack access to capital.

    60% confidence
  • Skalar has become expert at understanding which customer acquisition risks are sufficiently predictable and profitable to be underwritable.

    60% confidence
  • Capital flowing into and out of the growth stage has left strong-performing Latin American companies struggling to raise the equity needed to keep growing; Skalar fills that gap.

    60% confidence
  • Skalar only gets repaid as the financed companies get repaid by their customers.

    60% confidence
  • Monashees does not have access to the confidential operating data that startups provide to Skalar during its evaluation process.

    60% confidence
  • The best companies match capital sources to uses: equity for unstructured R&D bets, duration-matched capital for predictable investments like customer acquisition; most Latin American tech companies have never had that choice until Skalar.

    60% confidence
  • Skalar's structure is different because it absorbs most downside risk, which incentivizes it to avoid burdening client companies with credit risk.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Sources reconciled: no open conflicts right now.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,959
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,959 facts checked against source5,585 source documents archived
Query this data → isubstrate.com